Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.
Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.
Follow Bret on Twitter: @Bret_Jensen.
| Apr 25, 2018 | 1:00 PM EDT
Homebuilders and industrial names are seeing good results.
| Apr 23, 2018 | 10:00 AM EDT
I think M&A activity will pick up markedly going forward across the industry.
| Apr 20, 2018 | 1:30 PM EDT
Secondary offerings create buying opportunities.
| Apr 18, 2018 | 1:00 PM EDT
A look at three names to consider in the biotech and biopharma space.
| Apr 16, 2018 | 2:26 PM EDT
Data and industry conferences will likely be catalysts for shares in the space.
| Apr 15, 2018 | 10:00 AM EDT
Here are some smaller names I have my eye on as the season heats up.
| Apr 13, 2018 | 2:30 PM EDT
Here are some smaller names I have my eye on.
| Apr 11, 2018 | 1:00 PM EDT
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
| Apr 11, 2018 | 10:28 AM EDT
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
| Apr 09, 2018 | 11:40 AM EDT
A look at possible second-quarter M&A activity in the biotech sector.
